<DOC>
<DOCNO>
EP-0013788
</DOCNO>
<TEXT>
<DATE>
19800806
</DATE>
<IPC-CLASSIFICATIONS>
C07D-471/00 A61P-25/00 C07D-215/20 A61K-31/435 C07D-215/22 C07D-215/54 <main>C07D-471/04</main> C07D-471/04 C07D-215/227 A61K-31/47 C07D-215/00 A61P-43/00 
</IPC-CLASSIFICATIONS>
<TITLE>
octahydro-2h-pyrrolo(3,4-g)quinolines, process for their preparation and pharmaceutical compositions containing them.
</TITLE>
<APPLICANT>
lilly co elius<sep>eli lilly and company  <sep>eli lilly and company307, east mccarty streetindianapolis indiana 46285us<sep>eli lilly and company<sep>
</APPLICANT>
<INVENTOR>
back nicholas james<sep>kornfeld edmund carl<sep>back, nicholas james<sep>kornfeld, edmund carl<sep>back, nicholas james4269 burkhartstreet, e. driveindianapolis, indianaus<sep>kornfeld, edmund carl5159, east 76th courtindianapolis, indianaus<sep>back, nicholas james<sep>kornfeld, edmund carl<sep>back, nicholas james4269 burkhartstreet, e. driveindianapolis, indianaus<sep>kornfeld, edmund carl5159, east 76th courtindianapolis, indianaus<sep>
</INVENTOR>
<ABSTRACT>
octahydro-2h-pyrrolo[3,4-g]quinolines, useful as dop­ amine agonists, particularly as inhibitors of prolactin secre­ tion and in treatment of parkinsonism, are described here­ in.  these novel compounds are prepared by reacting a  2-alkylcarbonyloctahydro-2h-pyrrolo[3,4-g]quinoline with  base.  
</ABSTRACT>
</TEXT>
</DOC>
